Free Trial
LON:4BB

4basebio Interim Earnings Results & Report

4basebio logo
GBX 517.50 -0.50 (-0.10%)
As of 11:41 AM Eastern

4basebio reported Interim earnings on September 29, 2025. The company reported EPS of -GBX 50.

Earnings Announcement Details

Quarter
Interim
Time
Before Market Opens

4basebio EPS Results

Actual EPS
-GBX 50
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

4basebio Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

4basebio Interim Earnings FAQ

4basebio (LON:4BB) reported earnings of -GBX 50 per share for Interim. The report was announced on Monday, September 29, 2025.

4basebio Earnings Headlines

4basebio: Turning clinical credibility into commercial growth
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
4basebio Plc - Result of General Meeting
4basebio Plc - Result of General Meeting
See More 4basebio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 4basebio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 4basebio and other key companies, straight to your email.

About 4basebio

4basebio (LON:4BB) is a specialist life sciences group focused on supplying therapeutic synthetic DNA for gene therapies and gene-based vaccines and providing solutions for effective and safe delivery of DNA/RNA based products to patients. Our focus is the development of high quality, GMP grade synthetic DNA as well as non-viral nanoparticles which can efficiently and safely deliver fully functional genes to patients. These products and technologies are also available for customers and partners with whom we endeavor to combine our capabilities and know-how to develop gene therapy solutions for clinical development and commercialisation.

View 4basebio Profile